| 產(chǎn)品編號(hào) | bs-19051R-FITC |
| 英文名稱(chēng) | Rabbit Anti-NCOA4/FITC Conjugated antibody |
| 中文名稱(chēng) | FITC標(biāo)記的核受體共激活因子4抗體 |
| 別 名 | 70 kDa androgen receptor activator; 70 kDa androgen receptor coactivator; 70 kDa AR activator; 70 kDa AR-activator; Androgen receptor coactivator 70 kD; Androgen receptor coactivator 70 kDa protein; Androgen receptor-associated protein of 70 kDa; ARA 70; ARA70; DKFZp762E1112; ELE 1; ELE1; ELE1/ret TK; NCOA 4; NCoA-4; NCOA4; NCOA4_HUMAN; Nuclear receptor coactivator 4; Papillary thyroid carcinoma 3; PTC 3; PTC3; RET activating gene ELE1; Ret activating protein ELE1; Ret-activating protein ELE1; RFG. |
| 規(guī)格價(jià)格 | 100ul/2980元 購(gòu)買(mǎi) 大包裝/詢(xún)價(jià) |
| 說(shuō) 明 書(shū) | 100ul |
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 信號(hào)轉(zhuǎn)導(dǎo) 轉(zhuǎn)錄調(diào)節(jié)因子 激酶和磷酸酶 細(xì)胞膜受體 表觀遺傳學(xué) |
| 抗體來(lái)源 | Rabbit |
| 克隆類(lèi)型 | Polyclonal |
| 交叉反應(yīng) | (predicted: Human, Mouse, Rat, Pig, Cow, Horse, Sheep, ) |
| 產(chǎn)品應(yīng)用 | ICC=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 70kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human NCOA4 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: This gene encodes an androgen receptor coactivator. The encoded protein interacts with the androgen receptor in a ligand-dependent manner to enhance its transcriptional activity. Chromosomal translocations between this gene and the ret tyrosine kinase gene, also located on chromosome 10, have been associated with papillary thyroid carcinoma. Alternatively spliced transcript variants have been described. Pseudogenes are present on chromosomes 4, 5, 10, and 14. [provided by RefSeq, Feb 2009] Function: Enhances the androgen receptor transcriptional activity in prostate cancer cells. Ligand-independent coactivator of the peroxisome proliferator-activated receptor (PPAR) gamma. Subunit: Interacts with the androgen receptor and the retinoid X receptor (RXR) in a ligand-dependent manner. Tissue Specificity: Widely expressed. Also detected in adipose tissues and in different cell lines. Isoform Beta is only expressed in testis. DISEASE: Defects in NCOA4 are a cause of thyroid papillary carcinoma (TPC) [MIM:188550]. TPC is a common tumor of the thyroid that typically arises as an irregular, solid or cystic mass from otherwise normal thyroid tissue. Papillary carcinomas are malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. Note=A chromosomal aberration involving NCOA4 is found in thyroid papillary carcinomas. Inversion inv(10)(q11.2;q11.2) generates the RET/NCOA4 (PTC3) oncogene that has been found in sporadic and radiation-associated post-Chernobyl thyroid papillary carcinomas. Database links: Entrez Gene: 8031 Human Entrez Gene: 27057 Mouse Omim: 601984 Human SwissProt: Q13772 Human Unigene: 643658 Human Unigene: 709644 Human Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
